Reducing global disease burden of measles and rubella: report of the WHO Steering Committee on research related to measles and rubella vaccines and vaccination, 2005.
The WHO Steering Committee reviewed and evaluated the progress towards global control of measles and rubella and provided guidelines for future research activities concerning both diseases during its meeting in New Delhi, in April 2005. Global measles vaccination coverage increased from 71% in 1999 to 76% in 2004 and indigenous transmission was interrupted or kept at very low levels in many countries. However, Africa and Southeast Asia continue to experience endemic transmission and high mortality rates, despite a global mortality reduction of 39% between 1999 and 2003. On the basis of reports from countries with continued indigenous measles virus transmission, future control strategies as well as advantages and potential drawbacks of global measles eradication were discussed. Similarly the burden of rubella and congenital rubella syndrome (CRS) as well as the cost-effectiveness of rubella vaccination was assessed using different methods in several countries without vaccination programs. As measles and rubella viruses continue to circulate surveillance and control strategies need further optimization. RT-PCR was considered as an alternative method for laboratory diagnosis of CRS. The value of dried blood spots and oral fluid as alternative samples for measles and rubella IgG and IgM detection and genotype determination was evaluated. However further validation of these methods in different settings is required before their routine use can be recommended.
Muller
Claude P
CP
Institute of Immunology and WHO Collaborative Center for Measles and WHO European Regional Reference Laboratory for Measles and Rubella, Laboratoire National de Santé, Luxemburg. claude.muller@LNS.ETAT.LU
Kremer
Jacques R
JR
Best
Jennifer M
JM
Dourado
Ines
I
Triki
Henda
H
Reef
Susan
S
D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D006801:Humans; D008457:Measles / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control; D008458:Measles Vaccine / Q000008:administration & dosage*; D008459:Measles virus / Q000145:classification / Q000235:genetics / Q000276:immunology; D011247:Pregnancy; D012409:Rubella / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control; D012410:Rubella Syndrome, Congenital / Q000175:diagnosis / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control; D012411:Rubella Vaccine / Q000008:administration & dosage*; D012412:Rubella virus / Q000145:classification / Q000235:genetics / Q000276:immunology; D014611:Vaccination / Q000191:economics; D014944:World Health Organization
D008458:Measles Vaccine; D012411:Rubella Vaccine